Etentamig Clinical Trials (2026): 11 Studies for Multiple Myeloma & Relapsed/Refractory Multiple Myeloma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
11 Etentamig clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 5 indications (including Multiple Myeloma & Relapsed/Refractory Multiple Myeloma) and 2,510 total planned enrollment. 1 Phase 3 Etentamig trial are listed. 8 Etentamig clinical trials are actively recruiting at 107 U.S. sites across 28 states. Most recent activity: NCT07095452 (Jan 2042).
Where to Participate: All Etentamig Trial Sites in the U.S. (107 sites across 28 states)
Every actively recruiting Etentamigtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | University of Alabama at Birmingham - Main /ID# 261434 | Birmingham35233 | NCT06158841 | Map |
| AZ | Mayo Clinic Arizona /ID# 251405 | Phoenix85054 | NCT05650632 | Map |
| AZ | Mayo Clinic Hospital - Phoenix /ID# 263326 | Phoenix85054 | NCT06158841 | Map |
| AZ | Mayo Clinic Hospital Scottsdale /ID# 278349 | Scottsdale85259 | NCT07095452 | Map |
| AR | Highlands Oncology Group - Springdale /ID# 267742 | Springdale72762 | NCT05650632 | Map |
| CA | Beverly Hills Cancer Center /ID# 266921 | Beverly Hills90211 | NCT06896916 | Map |
| CA | Providence - St. Jude Medical Center /ID# 262031 | Fullerton92835 | NCT06158841 | Map |
| CA | VA Loma Linda Healthcare System /ID# 261015 | Loma Linda92357 | NCT06158841 | Map |
| CA | Cedars-Sinai Medical Center /ID# 261008 | Los Angeles90048 | NCT06158841 | Map |
| CA | Cedars-Sinai Medical Center /ID# 278238 | Los Angeles90048 | NCT07095452 | Map |
| CO | Rocky Mountain Cancer Centers - Aurora /ID# 268574 | Aurora80012 | NCT05650632 | Map |
| CO | Colorado Blood Cancer Institute /ID# 273129 | Denver80218 | NCT06892522 | Map |
| CO | Colorado Blood Cancer Institute /ID# 273751 | Denver80218 | NCT06896916 | Map |
| CO | Colorado Blood Cancer Institute /ID# 279080 | Denver80218 | NCT07095452 | Map |
| CO | Rocky Mountain Cancer Centers - Lone Tree /ID# 278320 | Lone Tree80124 | NCT06158841 | Map |
| DE | Medical Oncology Hematology Consultants /ID# 268560 | Newark19713 | NCT05650632 | Map |
| FL | Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 246230 | Jacksonville32256 | NCT06158841 | Map |
| FL | Mayo Clinic Hospital Jacksonville /ID# 263324 | Jacksonville32224 | NCT06158841 | Map |
| FL | Sylvester Comprehensive Cancer Center - University of Miami /ID# 255856 | Miami33136 | NCT06158854 | Map |
| FL | Moffitt Cancer Center /ID# 272628 | Tampa33612 | NCT06892522 | Map |
| GA | Winship Cancer Institute of Emory University /ID# 262525 | Atlanta30322 | NCT06158841 | Map |
| GA | Winship Cancer Institute of Emory University /ID# 274830 | Atlanta30322 | NCT06892522 | Map |
| GA | Winship Cancer Institute of Emory University /ID# 277667 | Atlanta30322 | NCT07095452 | Map |
| IL | University of Illinois Hospital and Health Sciences System /ID# 246349 | Chicago60607 | NCT06158841 | Map |
| IL | Nancy W. Knowles Cancer Center /ID# 271361 | Elmhurst60126 | NCT06158841 | Map |
| IL | Hope And Healing Cancer Services /ID# 268536 | Hinsdale60521 | NCT05650632 | Map |
| IL | Springfield Clinic - First /ID# 262266 | Springfield62702 | NCT06158841 | Map |
| IN | Fort Wayne Medical Oncology And Hematology /ID# 268179 | Fort Wayne46804 | NCT05650632 | Map |
| IN | Fort Wayne Medical Oncology And Hematology /ID# 278141 | Fort Wayne46804 | NCT07095452 | Map |
| LA | Our Lady Of The Lake Regional Medical Center /ID# 272780 | Baton Rouge70808 | NCT06158841 | Map |
| LA | Tulane University School of Medicine /ID# 251204 | New Orleans70112 | NCT05650632 | Map |
| MD | Center for Cancer and Blood Disorders-American Oncology Partners of Maryland /ID# 263637 | Bethesda20817 | NCT06158841 | Map |
| MA | Beth Israel Deaconess Medical Center /ID# 271535 | Boston02215 | NCT06158841 | Map |
| MA | Boston Medical Center /ID# 255066 | Boston02118 | NCT06158854 | Map |
| MA | Dana-Farber Cancer Institute /ID# 261554 | Boston02215 | NCT06158841 | Map |
| MI | Regents of the University of Michigan /ID# 261577 | Ann Arbor48109-1276 | NCT06158841 | Map |
| MI | Karmanos Cancer Institute - Detroit /ID# 266298 | Detroit48201 | NCT06158841 | Map |
| MI | Barbara Ann Karmanos Cancer Institute - McLaren Greater Lansing /ID# 259891 | Lansing48912 | NCT06158841 | Map |
| MN | Minnesota Oncology - Minneapolis Clinic /ID# 278720 | Minneapolis55404 | NCT07095452 | Map |
| MN | Mayo Clinic - Rochester /ID# 246228 | Rochester55905-0001 | NCT06158841 | Map |
| MN | Mayo Clinic - Rochester /ID# 251164 | Rochester55905-0001 | NCT05650632 | Map |
| MN | Mayo Clinic - Rochester /ID# 255258 | Rochester55905-0001 | NCT06158854 | Map |
| MN | Mayo Clinic Hospital Rochester /ID# 277886 | Rochester55905 | NCT07095452 | Map |
| MO | Washington University /ID# 266972 | St Louis63110 | NCT06896916 | Map |
| NE | NHO Revive Research Institute, LLC /ID# 267869 | Lincoln68506 | NCT05650632 | Map |
| NE | Nebraska Cancer Specialists - Omaha - Wright Street /ID# 276772 | Omaha68130 | NCT06158841 | Map |
| NE | Nebraska Cancer Specialists - Omaha - Wright Street /ID# 282497 | Omaha68130 | NCT05650632 | Map |
| NJ | Rutgers Cancer Institute of New Jersey /ID# 266833 | New Brunswick08901 | NCT06896916 | Map |
| NY | New York Cancer & Blood Specialists - Bay Shore /ID# 261524 | Bay Shore11706 | NCT06158841 | Map |
| NY | Columbia University Medical Center /ID# 255068 | New York10032-3729 | NCT06158854 | Map |
| NY | Icahn School of Medicine at Mount Sinai /ID# 255408 | New York10029 | NCT06158854 | Map |
| NY | Icahn School of Medicine at Mount Sinai /ID# 277844 | New York10029 | NCT07095452 | Map |
| NY | Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 270282 | New York10065 | NCT06896916 | Map |
| NY | Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 277946 | New York10065 | NCT07095452 | Map |
| NY | Memorial Sloan Kettering Cancer Center-Koch Center /ID# 251167 | New York10065-6007 | NCT05650632 | Map |
| NY | Memorial Sloan Kettering Cancer Center-Koch Center /ID# 255073 | New York10065-6007 | NCT06158854 | Map |
| NY | Mt Sinai /ID# 251166 | New York10029-6542 | NCT05650632 | Map |
| NY | Weill Cornell Medical College /ID# 272517 | New York10065 | NCT06892522 | Map |
| NY | Weill Cornell Medicine Myeloma Center /ID# 278216 | New York10065 | NCT07095452 | Map |
| NY | Eastchester Center for Cancer Care /ID# 262952 | The Bronx10469 | NCT06158841 | Map |
| NC | University of North Carolina /ID# 251203 | Chapel Hill27514 | NCT05650632 | Map |
| NC | University of North Carolina /ID# 259854 | Chapel Hill27514 | NCT06158841 | Map |
| NC | University of North Carolina at Chapel Hill /ID# 274667 | Chapel Hill27514 | NCT06892522 | Map |
| NC | University of North Carolina at Chapel Hill /ID# 277708 | Chapel Hill27514 | NCT07095452 | Map |
| NC | Atrium Health Levine Cancer Institute /ID# 246199 | Charlotte28204 | NCT06158841 | Map |
| NC | Atrium Health Levine Cancer Institute /ID# 255074 | Charlotte28204 | NCT06158854 | Map |
| NC | Atrium Health Levine Cancer Institute /ID# 276193 | Charlotte28204-2990 | NCT06892522 | Map |
| NC | University Of North Carolina Health Care - Hillsborough Campus /ID# 278230 | Hillsborough27278 | NCT06896916 | Map |
| NC | Atrium Health Wake Forest Baptist Medical Center /ID# 251165 | Winston-Salem27157 | NCT05650632 | Map |
| NC | Atrium Health Wake Forest Baptist Medical Center /ID# 255851 | Winston-Salem27157 | NCT06158854 | Map |
| NC | Atrium Health Wake Forest Baptist Medical Center /ID# 274847 | Winston-Salem27157 | NCT06892522 | Map |
| OH | Oncology Hematology Care - Kenwood /ID# 272918 | Cincinnati45236 | NCT06892522 | Map |
| OH | University Of Cincinnati Medical Center /ID# 246415 | Cincinnati45219 | NCT06158841 | Map |
| OH | University Of Cincinnati Medical Center /ID# 251746 | Cincinnati45219 | NCT05650632 | Map |
| OH | Cleveland Clinic Main Campus /ID# 246183 | Cleveland44195 | NCT06158841 | Map |
| OR | Willamette Valley Cancer Institute and Research Center /ID# 267088 | Eugene97401 | NCT05650632 | Map |
| OR | Willamette Valley Cancer Institute and Research Center /ID# 278721 | Eugene97401 | NCT07095452 | Map |
| OR | Oregon Medical Research Center /ID# 255119 | Portland97239 | NCT06158854 | Map |
| OR | Oregon Medical Research Center /ID# 262335 | Portland97239 | NCT06158841 | Map |
| SC | Medical University of South Carolina /ID# 259692 | Charleston29425 | NCT06158841 | Map |
| TN | Baptist Memorial Hospital /ID# 270910 | Memphis38120 | NCT06158841 | Map |
| TN | The West Clinic /ID# 262444 | Memphis38120 | NCT06158841 | Map |
| TN | University of Tennessee Health Science Center /ID# 261622 | Memphis38103 | NCT06158841 | Map |
| TN | SCRI Oncology Partners /ID# 278353 | Nashville37203 | NCT07095452 | Map |
| TN | Vanderbilt Ingram Cancer Center /ID# 252470 | Nashville37232-0021 | NCT05650632 | Map |
| TN | Vanderbilt University Medical Center /ID# 261621 | Nashville37232-0011 | NCT06158841 | Map |
| TN | Vanderbilt University Medical Center. /ID# 273510 | Nashville37232 | NCT06158854 | Map |
| TX | Texas Oncology - Central/South Texas /ID# 268563 | Austin78705 | NCT05650632 | Map |
| TX | Texas Oncology - Dallas - Worth Street /ID# 280064 | Dallas75246 | NCT05650632 | Map |
| TX | Oncology Consultants /ID# 268323 | Houston77030 | NCT05650632 | Map |
| TX | Oncology Consultants /ID# 276774 | Houston77030 | NCT06158841 | Map |
| TX | Texas Oncology - The Woodlands /ID# 278726 | The Woodlands77380 | NCT07095452 | Map |
| TX | Texas Oncology - Northeast Texas /ID# 268877 | Tyler75702 | NCT05650632 | Map |
| TX | Texas Oncology - Northeast Texas /ID# 278304 | Tyler75702 | NCT06158841 | Map |
| TX | Texas Oncology - Northeast Texas /ID# 278725 | Tyler75702 | NCT07095452 | Map |
| VA | Virginia Cancer Specialists - Fairfax /ID# 262792 | Fairfax22031 | NCT06158841 | Map |
| VA | Virginia Cancer Specialists - Fairfax /ID# 268559 | Fairfax22031 | NCT05650632 | Map |
| VA | Virginia Cancer Specialists - Fairfax /ID# 278716 | Fairfax22031 | NCT07095452 | Map |
| VA | Virginia Oncology Associates - Norfolk (Lake Wright) /ID# 278314 | Norfolk23502 | NCT06158841 | Map |
| VA | VCU Massey Cancer Center: Dalton Oncology Clinic /ID# 261944 | Richmond23298 | NCT06158841 | Map |
| VA | Blue Ridge Cancer Care - Roanoke /ID# 278722 | Roanoke24014 | NCT07095452 | Map |
| WA | Fred Hutchinson Cancer Center. /ID# 267940 | Seattle98109-4405 | NCT05650632 | Map |
| WA | Swedish Medical Center - Seattle /ID# 268052 | Seattle98104 | NCT06896916 | Map |
| WA | University of Washington /ID# 261581 | Seattle98109 | NCT06158854 | Map |
| WA | Northwest Medical Specialties Tacoma /ID# 267117 | Tacoma98405 | NCT05650632 | Map |
| WA | Northwest Medical Specialties Tacoma /ID# 276281 | Tacoma98405 | NCT06158841 | Map |
| WI | Wisconsin Medical Center /ID# 255836 | Milwaukee53226 | NCT06158854 | Map |
Etentamig clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | not yet recruiting | Total |
|---|---|---|---|---|
| P1 | 2 | 3 | 5 | |
| P1/P2 | 2 | 2 | 4 | |
| P2/P3 | 1 | 1 | ||
| P3 | 1 | 1 |
Recruiting Etentamig clinical trials (8)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07095452 | A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | P2/P3 | Multiple Myeloma | 660 | Jan 2026 |
| NCT07420959 | ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia | P1/P2 | Recurrent Waldenstrom Macroglobulinemia | 38 | Mar 2026 |
| NCT07600151 | CONQUISTADOREtenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma | P1/P2 | Myeloma Multiple | 220 | Dec 2026 |
| NCT06896916 | IVStudy of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma | P1 | Multiple Myeloma | 135 | Aug 2025 |
| NCT06892522 | AEA Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib | P1/P2 | Multiple Myeloma | 440 | Jun 2025 |
| NCT06158854 | AEA Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion | P1/P2 | Immunoglobulin Light Chain (AL) Amyloidosis | 76 | Apr 2024 |
| NCT05650632 | IVA Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma | P1 | Multiple Myeloma | 210 | Mar 2023 |
| NCT06158841 | CERVINOStudy Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | P3 | Multiple Myeloma | 380 | May 2024 |
Etentamig clinical trials by indication
Multiple Myeloma (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07095452 | — | P2/P3 | recruiting | A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant |
| NCT06896916 | IV | P1 | recruiting | Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma |
| NCT06892522 | AE | P1/P2 | recruiting | A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib |
| NCT05650632 | IV | P1 | recruiting | A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma |
| NCT06223516 | SC | P1 | active not recruiting | Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma |
| NCT06158841 | CERVINO | P3 | recruiting | Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma |
Relapsed/Refractory Multiple Myeloma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05259839 | IV | P1 | active not recruiting | A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma |
| NCT05286229 | IV | P1 | active not recruiting | A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan |
Myeloma Multiple (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07600151 | CONQUISTADOR | P1/P2 | not yet recruiting | Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma |
Recurrent Waldenstrom Macroglobulinemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07420959 | — | P1/P2 | not yet recruiting | ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia |
Immunoglobulin Light Chain (AL) Amyloidosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06158854 | AE | P1/P2 | recruiting | A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion |
Etentamig pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| CERVINO | NCT06158841 | P3 | recruiting | Multiple Myeloma | 380 | — |
All Etentamig trials (11)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07095452 | A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | P2/P3 | recruiting | 660 | AbbVie | Jan 2026 | |
| NCT07420959 | ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia | P1/P2 | not yet recruiting | 38 | Mayo Clinic | Mar 2026 | |
| NCT07600151 | CONQUISTADOR | Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma | P1/P2 | not yet recruiting | 220 | Universitätsklinikum Hamburg-Eppendorf | Dec 2026 |
| NCT06896916 | IV | Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma | P1 | recruiting | 135 | AbbVie | Aug 2025 |
| NCT06892522 | AE | A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib | P1/P2 | recruiting | 440 | AbbVie | Jun 2025 |
| NCT05259839 | IV | A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma | P1 | active not recruiting | 283 | AbbVie | Oct 2022 |
| NCT06158854 | AE | A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion | P1/P2 | recruiting | 76 | AbbVie | Apr 2024 |
| NCT05650632 | IV | A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma | P1 | recruiting | 210 | AbbVie | Mar 2023 |
| NCT06223516 | SC | Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma | P1 | active not recruiting | 60 | AbbVie | Jun 2024 |
| NCT06158841 | CERVINO | Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | P3 | recruiting | 380 | AbbVie | May 2024 |
| NCT05286229 | IV | A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan | P1 | active not recruiting | 8 | AbbVie | Mar 2022 |
Etentamig clinical trials: frequently asked questions
- How many Etentamig clinical trials are there?
- 11 Etentamig clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 6 are actively recruiting participants.
- Are Etentamig clinical trials recruiting in 2026?
- Yes — 6 Etentamig trials are actively recruiting in 2026, with 107 U.S. sites across 28 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Etentamig being studied for?
- Etentamig is being studied for Multiple Myeloma, Relapsed/Refractory Multiple Myeloma, Immunoglobulin Light Chain (AL) Amyloidosis, Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia and 2 more. The trials are grouped by indication on this page.
- What phase is Etentamig in?
- Etentamig clinical trials span 1 Phase 3, 5 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Etentamig clinical trials?
- The lead sponsor across the most Etentamig trials is AbbVie, with 2 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Etentamigas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: